Fig. 1.
Patient selection: 1011 patients with glioblastoma at Dana-Farber Cancer Institute who had in-house targeted panel sequencing between 2013 and 2019 were retrospectively identified. All secondary GBMs, IDH-mutant tumors and patients without consistent follow-up were excluded. This algorithm resulted in 557 patients which were included in the final cohort.